TY - JOUR
T1 - Effectiveness of taxanes-based chemotherapy against hormone-refractory prostate carcinoma
AU - Shiroki, Ryoichi
AU - Kuwahara, Yoshitaka
AU - Sakurai, Takahiko
AU - Maruyama, Takahiro
AU - Hoshinaga, Kiyotaka
N1 - Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2006/6
Y1 - 2006/6
N2 - We performed an investigative and clinical study of docetaxel, and evaluated its efficacy against hormone-refractory prostate carcinoma (HRPC). In an in vitro experiment, docetaxel suppressed the human prostate cell line proliferation not only in an androgen-dependent cell line, LNCaP, but also in androgen-independent cell line, PC-3, in a dose-dependent manner. In an in vivo experiment applying an SCID mouse xenograft model with PC-3, docetaxel administration suppressed the tumor growth more than 95%. In a clinical study, eight cases were enrolled to low-dose (20 mg/m 2/wk) weekly regimen and an other eight to high-dose (60 mg/m 2/wk) administration of docetaxel every three weeks. A prostate specific antigen (PSA) decline of more than 50% were observed in 4 (50%) in the low-dose group and 5 (63%) in the high-dose group. The median time to progression and overall survival were 8.5 and 13.2 months in the low-dose group and more than 5.5 and 8.5 months in the high-dose one, respectively. This regimen was well tolerated, and the incidence of adverse effect was relatively low and light. Grade 3 neutropenia or leukocytopenia without fever was seen in three patients (18.8%). Only one patient required administration of granulocyte-colony stimulating factor because of neutropenia. No other grade 3 or 4 toxicity was observed. In conclusion, docetaxel-based chemotherapy was well tolerated and an active treatment for HRPC cases.
AB - We performed an investigative and clinical study of docetaxel, and evaluated its efficacy against hormone-refractory prostate carcinoma (HRPC). In an in vitro experiment, docetaxel suppressed the human prostate cell line proliferation not only in an androgen-dependent cell line, LNCaP, but also in androgen-independent cell line, PC-3, in a dose-dependent manner. In an in vivo experiment applying an SCID mouse xenograft model with PC-3, docetaxel administration suppressed the tumor growth more than 95%. In a clinical study, eight cases were enrolled to low-dose (20 mg/m 2/wk) weekly regimen and an other eight to high-dose (60 mg/m 2/wk) administration of docetaxel every three weeks. A prostate specific antigen (PSA) decline of more than 50% were observed in 4 (50%) in the low-dose group and 5 (63%) in the high-dose group. The median time to progression and overall survival were 8.5 and 13.2 months in the low-dose group and more than 5.5 and 8.5 months in the high-dose one, respectively. This regimen was well tolerated, and the incidence of adverse effect was relatively low and light. Grade 3 neutropenia or leukocytopenia without fever was seen in three patients (18.8%). Only one patient required administration of granulocyte-colony stimulating factor because of neutropenia. No other grade 3 or 4 toxicity was observed. In conclusion, docetaxel-based chemotherapy was well tolerated and an active treatment for HRPC cases.
KW - Chemotherapy
KW - Hormone-refractory prostate carcinoma
KW - Taxanes
UR - http://www.scopus.com/inward/record.url?scp=33745757391&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745757391&partnerID=8YFLogxK
M3 - Article
C2 - 16848362
AN - SCOPUS:33745757391
SN - 0018-1994
VL - 52
SP - 481
EP - 485
JO - Acta Urologica Japonica
JF - Acta Urologica Japonica
IS - 6
ER -